HCA Healthcare, Inc. (NYSE:HCA) Announces Quarterly Dividend of $0.66

HCA Healthcare, Inc. (NYSE:HCA) declared a quarterly dividend on Friday, October 25th, RTT News reports. Stockholders of record on Friday, December 13th will be paid a dividend of 0.66 per share on Friday, December 27th. This represents a $2.64 annualized dividend and a dividend yield of 0.73%.

HCA Healthcare has a payout ratio of 10.6% meaning its dividend is sufficiently covered by earnings. Analysts expect HCA Healthcare to earn $24.95 per share next year, which means the company should continue to be able to cover its $2.64 annual dividend with an expected future payout ratio of 10.6%.

HCA Healthcare Stock Down 8.8 %

NYSE HCA opened at $363.75 on Friday. The stock has a market cap of $93.87 billion, a PE ratio of 17.08, a P/E/G ratio of 1.52 and a beta of 1.67. The company has a current ratio of 1.06, a quick ratio of 0.94 and a debt-to-equity ratio of 27.11. HCA Healthcare has a 12 month low of $220.55 and a 12 month high of $417.14. The stock’s 50 day moving average is $395.26 and its 200 day moving average is $352.63.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings results on Tuesday, July 23rd. The company reported $5.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.97 by $0.53. HCA Healthcare had a net margin of 8.40% and a return on equity of 553.13%. The company had revenue of $17.49 billion for the quarter, compared to the consensus estimate of $17.05 billion. During the same period in the previous year, the firm posted $4.29 EPS. HCA Healthcare’s revenue for the quarter was up 10.3% compared to the same quarter last year. Research analysts predict that HCA Healthcare will post 22.48 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Michael S. Cuffe sold 8,358 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $385.42, for a total value of $3,221,340.36. Following the completion of the sale, the executive vice president now owns 29,678 shares in the company, valued at approximately $11,438,494.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other HCA Healthcare news, EVP Michael S. Cuffe sold 8,358 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the completion of the sale, the executive vice president now owns 29,678 shares in the company, valued at $11,438,494.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Kathleen M. Whalen sold 2,987 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $363.51, for a total value of $1,085,804.37. Following the completion of the transaction, the senior vice president now directly owns 9,454 shares of the company’s stock, valued at approximately $3,436,623.54. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,345 shares of company stock valued at $5,747,945 over the last three months. 1.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Barclays raised their price target on HCA Healthcare from $376.00 to $396.00 and gave the company an “overweight” rating in a report on Wednesday, July 24th. Leerink Partners increased their price objective on shares of HCA Healthcare from $367.00 to $396.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Truist Financial upped their target price on shares of HCA Healthcare from $390.00 to $430.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Cantor Fitzgerald restated an “overweight” rating and set a $392.00 price objective on shares of HCA Healthcare in a research report on Tuesday, October 1st. Finally, KeyCorp started coverage on shares of HCA Healthcare in a report on Friday, October 11th. They set an “overweight” rating and a $475.00 price target on the stock. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, HCA Healthcare presently has a consensus rating of “Moderate Buy” and an average price target of $377.17.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.